Nilotinib Zentiva (Nilotinib)

Nilotinib binds to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, preventing the enzyme from phosphorylating downstream proteins. This blockade stops the signaling pathways that promote uncontrolled proliferation of leukemic cells, leading to reduced disease activity.

The prescribed dose of Nilotinib Zentiva is determined by the treating physician based on the patient’s clinical condition, disease phase, and tolerability. Dosing instructions are individualized and should follow the prescriber’s written order.

The safety of nilotinib in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding is generally not recommended while on therapy.

To request Nilotinib Zentiva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency than first‑generation agents such as imatinib. It is often selected for patients who have resistance or intolerance to earlier tyrosine kinase inhibitors, providing deeper molecular responses in many cases.

Store Nilotinib Zentiva tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and avoid storing in humid or excessively hot environments.

Nilotinib Zentiva is taken orally, usually with a low‑fat meal to improve absorption. The tablets should be swallowed whole with water and not crushed or chewed. Dosing times are typically twice daily, but the exact schedule is set by the prescriber.

Serious adverse events include QT interval prolongation, which can lead to life‑threatening arrhythmias, and severe hepatotoxicity or pancreatitis. Patients should undergo regular ECG monitoring, liver function tests, and be educated about symptoms such as palpitations, abdominal pain, or jaundice.

Nilotinib is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients. It should be avoided in individuals with uncontrolled cardiac arrhythmias, significant electrolyte disturbances, or severe hepatic impairment unless a specialist determines the benefits outweigh the risks.